CRISPR

Join host Ryan Cole as he cuts through the CRISPR hype to reveal what's actually happening in labs and clinics. From the first approved gene-editing cure to the engineering challenges of editing DNA in living patients, this series explores the gap between promise and practice in genetic medicine. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Ryan Cole explores how CRISPR evolved from simple gene-cutting scissors into a sophisticated genome engineering workshop. From MIT's PASTE technology inserting DNA base pairs to CRISPR-recombinase hybrids enabling one-step gene replacement, Cole examines breakthrough tools reshaping genetic medicine and the gap between laboratory capabilities and patient deployment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Host Ryan Cole explores CRISPR's biggest challenge: delivery. While gene editing is proven, safely getting edits into patients remains medicine's hardest problem. Cole examines viral vectors versus lipid nanoparticles, breakthrough trials for blindness and liver disease, and why delivery methods determine which diseases we can treat. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Ryan Cole examines Casgevy, the world's first approved CRISPR medicine for sickle cell disease and beta thalassemia. While revolutionary, delivering this autologous gene therapy faces massive challenges: a $2.2 million price tag, months-long manufacturing, only 50 global treatment centers, and access barriers in regions with highest disease burden. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Ryan Cole examines Casgevy, the world's first approved CRISPR medicine for sickle cell disease and beta thalassemia. While revolutionary, delivering this autologous gene therapy faces massive challenges: a $2.2 million price tag, months-long manufacturing, only 50 global treatment centers, and access barriers in regions with highest disease burden. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.